Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...

The Novo Nordisk Patient Assistance Program ... is also available in a pill format called Rybelsus. When used correctly, Ozempic can help you manage your Type 2 diabetes while also aiding in ...

A Novo Nordisk spokesperson told Newsweek via email: "NAION is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

In the fourth quarter of 2024, Novo Nordisk reported strong performance across its GLP-1 portfolio. Ozempic and Rybelsus, the oral formulation of semaglutide, exceeded consensus expectations.